MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
1.400
-0.020
-1.41%
After Hours: 1.380 -0.02 -1.43% 19:30 12/05 EST
OPEN
1.420
PREV CLOSE
1.420
HIGH
1.445
LOW
1.381
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
1.660
52 WEEK LOW
0.2836
MARKET CAP
508.76M
P/E (TTM)
-7.3918
1D
5D
1M
3M
1Y
5Y
1D
Lexicon Pharma To Present Clinical Data On Adipose Tissue Distribution In Non-Diabetic Patients Treated With Sotagliflozin At CVCT 2025
Benzinga · 2d ago
Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients
Reuters · 2d ago
CLINICAL DATA ON EFFECT OF SOTAGLIFLOZIN ON ADIPOSE DISTRIBUTION IN NON-DIABETIC PATIENTS WILL BE PRESENTED AT THE 2025 CARDIO VASCULAR CLINICAL TRIALISTS FORUM
Reuters · 2d ago
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well
Seeking Alpha · 3d ago
Weekly Report: what happened at LXRX last week (1124-1128)?
Weekly Report · 6d ago
Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 11/28 13:17
Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences
Reuters · 11/25 13:30
Weekly Report: what happened at LXRX last week (1117-1121)?
Weekly Report · 11/24 09:38
More
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.